(AIM : SAR)

29 November 2013

Sareum Holdings plc

(“Sareum” or “the Company”)

Total Voting Rights

 

The Company announces that, pursuant to the requirements of the Disclosure and Transparency Rules, the total number of voting rights in respect of each class of share in issue and admitted to trading on AIM at the date of this announcement is as follows:

 

 

Total number of shares in issue

Total number of voting rights

Ordinary Shares of 0.025 pence each

1,800,038,273

1,800,038,273

 

 

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For further information:

 

Sareum Holdings plc

Tim Mitchell

 

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements

 

020 7628 2200

Hybridan LLP (Broker)

Claire Noyce / William Lynne

 

020 7947 4350 / 4361

The Communications Portfolio Limited (Media enquiries)

Ariane Comstive

Ariane.comstive@communications-portfolio.co.uk

 

020 7536 2028

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licencing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, TYK2 and VEGFR-3 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

 

For more information, please visit www.sareum.co.uk